医学
胃排空
艾塞那肽
血糖性
胰高血糖素样肽-1
糖尿病
肠促胰岛素
利拉鲁肽
2型糖尿病
药理学
2型糖尿病
药物治疗
内科学
内分泌学
胰高血糖素样肽1受体
胰高血糖素
胰岛素
兴奋剂
受体
胃
作者
Mary J. Elder,Emily Ashjian
标识
DOI:10.1177/08971900211049032
摘要
Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying. These properties make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are many FDA-approved GLP-1 agonists on the market today, several of which have demonstrated benefit beyond improving glycemic control. Given the beneficial effects of GLP-1 agonists in patients with T2DM, new drugs are in development that combine the mechanism of action of GLP-1 receptor agonism with novel mechanisms and with drugs that promote GLP-1 secretion. These agents are designed to improve glycemic control and target greater body weight reduction. This article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI